171 related articles for article (PubMed ID: 27614395)
1. Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-muscle Invasive Bladder Cancer in Asia.
Ieda T; Muto S; Shimizu F; Taguri M; Yanada S; Kitamura K; Terai K; Saito K; Ogishima T; Nagata M; Ide H; Okegawa T; Wakumoto Y; Sakamoto Y; Tsujimura A; Yamaguchi R; Nutahara K; Horie S
EBioMedicine; 2016 Oct; 12():98-104. PubMed ID: 27614395
[TBL] [Abstract][Full Text] [Related]
2. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
3. Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-Muscle Invasive Bladder Cancer in the Han Chinese Population.
Wang Z; Gao W; Li J; Wang T; Zhu M; Duan Y
J Cancer; 2020; 11(7):1668-1678. PubMed ID: 32194779
[No Abstract] [Full Text] [Related]
4. Selection of adjuvant intravesical therapies using the European Organization for Research and Treatment of Cancer scoring system in patients at intermediate risk of non-muscle-invasive bladder cancer.
Ofude M; Kitagawa Y; Yaegashi H; Izumi K; Ueno S; Kadono Y; Konaka H; Mizokami A; Namiki M
J Cancer Res Clin Oncol; 2015 Jan; 141(1):161-8. PubMed ID: 25108407
[TBL] [Abstract][Full Text] [Related]
5. [Value of detection of preoperative urinary soluble Fas expression in predicting the recurrence of non-muscle invasive bladder cancer].
Yang H; Guo Y; Wang Z; Wang Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Jan; 41(1):24-9. PubMed ID: 26819421
[TBL] [Abstract][Full Text] [Related]
6. Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC).
Nicklas AP; Kramer MW; Serth J; Hennenlotter J; Hupe MC; Reimer DU; Stenzl A; Merseburger AS; Kuczyk MA; von Klot CJ
Adv Ther; 2018 Nov; 35(11):2054-2068. PubMed ID: 30232708
[TBL] [Abstract][Full Text] [Related]
7. EORTC risk tables are more suitable for Chinese patients with nonmuscle-invasive bladder cancer than AUA risk stratification.
Wang H; Ding W; Jiang G; Gou Y; Sun C; Chen Z; Xu K; Xia G
Medicine (Baltimore); 2018 Sep; 97(36):e12006. PubMed ID: 30200080
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.
Soukup V; Čapoun O; Cohen D; Hernández V; Babjuk M; Burger M; Compérat E; Gontero P; Lam T; MacLennan S; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Yuan Y; Zigeuner R
Eur Urol; 2017 Nov; 72(5):801-813. PubMed ID: 28457661
[TBL] [Abstract][Full Text] [Related]
9. Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer - examining the utility of classifying Ta bladder cancer based on size.
Tully KH; Moschini M; von Rundstedt FE; Aziz A; Kluth LA; Necchi A; Rink M; Hendricksen K; Sargos P; Vetterlein MW; Seiler R; Poyet C; Krajewski W; Fajkovic H; Shariat SF; Xylinas E; Roghmann F
Urol Oncol; 2020 Nov; 38(11):851.e19-851.e25. PubMed ID: 32739227
[TBL] [Abstract][Full Text] [Related]
10. STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer.
Taber A; Park Y; Lelo A; Prip F; Xiao J; Berry DL; Chaldekas K; Jensen JB; Philips G; Kim JS; Harris BT; Dyrskjøt L; Waldman T
Urol Oncol; 2021 Jul; 39(7):438.e1-438.e9. PubMed ID: 33712344
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
Lin YL; Wang YL; Ma JG; Li WP
J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
[TBL] [Abstract][Full Text] [Related]
12. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
[TBL] [Abstract][Full Text] [Related]
13. Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection.
Zhang G; Steinbach D; Grimm MO; Horstmann M
World J Urol; 2019 Dec; 37(12):2699-2705. PubMed ID: 30911812
[TBL] [Abstract][Full Text] [Related]
14. Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel.
Soukup V; Čapoun O; Cohen D; Hernández V; Burger M; Compérat E; Gontero P; Lam T; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Yuan Y; Zigeuner R; Babjuk M
Eur Urol Focus; 2020 May; 6(3):479-489. PubMed ID: 30470647
[TBL] [Abstract][Full Text] [Related]
15. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
16. Predicting recurrence and progression in Chinese patients with nonmuscle-invasive bladder cancer using EORTC and CUETO scoring models.
Xu T; Zhu Z; Zhang X; Wang X; Zhong S; Zhang M; Shen Z
Urology; 2013 Aug; 82(2):387-93. PubMed ID: 23759377
[TBL] [Abstract][Full Text] [Related]
17. Deep Learning-based Recalibration of the CUETO and EORTC Prediction Tools for Recurrence and Progression of Non-muscle-invasive Bladder Cancer.
Jobczyk M; Stawiski K; Kaszkowiak M; Rajwa P; Różański W; Soria F; Shariat SF; Fendler W
Eur Urol Oncol; 2022 Feb; 5(1):109-112. PubMed ID: 34092528
[TBL] [Abstract][Full Text] [Related]
18. Use and Validation of the AUA/SUO Risk Grouping for Nonmuscle Invasive Bladder Cancer in a Contemporary Cohort.
Ritch CR; Velasquez MC; Kwon D; Becerra MF; Soodana-Prakash N; Atluri VS; Almengo K; Alameddine M; Kineish O; Kava BR; Punnen S; Parekh DJ; Gonzalgo ML
J Urol; 2020 Mar; 203(3):505-511. PubMed ID: 31609178
[TBL] [Abstract][Full Text] [Related]
19. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
[TBL] [Abstract][Full Text] [Related]
20. External validation of European Association of Urology NMIBC risk scores to predict progression after transurethral resection of bladder tumor in Korean patients with non-muscle-invasive bladder cancer.
Kim JY; Lee DB; Song WH; Lee SS; Park SW; Nam JK
Investig Clin Urol; 2022 Sep; 63(5):531-538. PubMed ID: 36067998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
